A Redox‐Responsive Nanovaccine Combined with A2A Receptor Antagonist for Cancer Immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Redox‐Responsive Nanovaccine Combined with A2A Receptor Antagonist for Cancer Immunotherapy
Authors
Keywords
-
Journal
Advanced Healthcare Materials
Volume -, Issue -, Pages 2101222
Publisher
Wiley
Online
2021-09-08
DOI
10.1002/adhm.202101222
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Escherichia coli Combined with Immunogenic Cell Death for Cancer Immunotherapy
- (2021) Baicheng Wei et al. NANO LETTERS
- A Size‐Changeable Collagenase‐Modified Nanoscavenger for Increasing Penetration and Retention of Nanomedicine in Deep Tumor Tissue
- (2020) Funeng Xu et al. ADVANCED MATERIALS
- A NIR light triggered disintegratable nanoplatform for enhanced penetration and chemotherapy in deep tumor tissues
- (2020) Xiang Xiong et al. BIOMATERIALS
- Stepwise dual targeting and dual responsive polymer micelles for mitochondrion therapy
- (2020) Xiaobin Zhang et al. JOURNAL OF CONTROLLED RELEASE
- A Biomimetic Polymer Magnetic Nanocarrier Polarizing Tumor‐Associated Macrophages for Potentiating Immunotherapy
- (2020) Lingqiao Liu et al. Small
- Redox‐Responsive Self‐Assembled Nanoparticles for Cancer Therapy
- (2020) Dandan Li et al. Advanced Healthcare Materials
- Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression
- (2020) Senbiao Chen et al. Nano Today
- Metastasis and immune evasion from extracellular cGAMP hydrolysis
- (2020) Jun Li et al. Cancer Discovery
- Efficient delivery of BRD4 inhibitor by glutathione-sensitive nanoparticle to suppress gallbladder cancer through inhibiting NF-κB signaling
- (2020) Qiongcong Xu et al. Applied Materials Today
- Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade
- (2019) Fangyuan Zhou et al. ADVANCED MATERIALS
- Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1
- (2019) Hairui Wang et al. NANO LETTERS
- Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator
- (2019) Ruolin Lu et al. JOURNAL OF CONTROLLED RELEASE
- Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
- (2019) Xiaopin Duan et al. Nature Communications
- A Designer Scaffold with Immune Nanoconverters for Reverting Immunosuppression and Enhancing Immune Checkpoint Blockade Therapy
- (2019) Hathaichanok Phuengkham et al. ADVANCED MATERIALS
- Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses
- (2019) Xiang Liu et al. BIOMATERIALS
- Multifunctional nanoplatforms for subcellular delivery of drugs in cancer therapy
- (2019) Xing Guo et al. PROGRESS IN MATERIALS SCIENCE
- Nanoparticle-mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
- (2018) Xiaopin Duan et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Personalized vaccines for cancer immunotherapy
- (2018) Ugur Sahin et al. SCIENCE
- Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses
- (2018) Lutz Nuhn et al. ADVANCED MATERIALS
- The 2018 Nobel Prize in Physiology or Medicine: An exemplar of bench to bedside in immunology
- (2018) Zuhair K. Ballas JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
- (2018) Qian Chen et al. Nature Nanotechnology
- Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma
- (2017) Si-Rui Ma et al. Molecular Cancer
- A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
- (2017) Melanie Mediavilla-Varela et al. NEOPLASIA
- Codelivery of a π-π Stacked Dual Anticancer Drug Combination with Nanocarriers for Overcoming Multidrug Resistance and Tumor Metastasis
- (2016) Xiao Wei et al. ADVANCED FUNCTIONAL MATERIALS
- Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
- (2016) Arabella Young et al. CANCER CELL
- Immunosuppressive activities of adenosine in cancer
- (2016) Bertrand Allard et al. CURRENT OPINION IN PHARMACOLOGY
- In Situ Formation of Nanofibers from Purpurin18-Peptide Conjugates and the Assembly Induced Retention Effect in Tumor Sites
- (2015) Di Zhang et al. ADVANCED MATERIALS
- Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
- (2015) Michael S. Goldberg CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell exclusion, immune privilege, and the tumor microenvironment
- (2015) J. A. Joyce et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
- (2015) Robert D. Leone et al. Computational and Structural Biotechnology Journal
- Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment
- (2014) C. Cekic et al. CANCER RESEARCH
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- The Suppressive Tumor Microenvironment: A Challenge in Cancer Immunotherapy
- (2011) Elizabeth A. Vasievich et al. MOLECULAR PHARMACEUTICS
- The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management
- (2009) Sujana Movva et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- TLR7 and TLR8 as targets in cancer therapy
- (2008) M P Schön et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search